Last update 07 Jun 2025

Ritlecitinib Tosilate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ritlecitinib, Ritlecitinib Tosylate, PF 06651600
+ [7]
Action
inhibitors
Mechanism
JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors), TEC inhibitors(tec protein tyrosine kinase inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (23 Jun 2023),
RegulationBreakthrough Therapy (United States), Breakthrough Therapy (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H27N5O4S
InChIKeyYOZLVAFWYLSRRN-VZXYPILPSA-N
CAS Registry2192215-81-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alopecia Areata
United States
23 Jun 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonsegmental vitiligoPhase 3
United States
01 Dec 2022
Nonsegmental vitiligoPhase 3
China
01 Dec 2022
Nonsegmental vitiligoPhase 3
Japan
01 Dec 2022
Nonsegmental vitiligoPhase 3
Australia
01 Dec 2022
Nonsegmental vitiligoPhase 3
Bulgaria
01 Dec 2022
Nonsegmental vitiligoPhase 3
Canada
01 Dec 2022
Nonsegmental vitiligoPhase 3
Germany
01 Dec 2022
Nonsegmental vitiligoPhase 3
India
01 Dec 2022
Nonsegmental vitiligoPhase 3
Italy
01 Dec 2022
Nonsegmental vitiligoPhase 3
Mexico
01 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(Ritlecitinib 100 mg Oral Solution (Fasted))
wzhxbfspbd(zocvzpqlgv) = szkyiklrbg ntcnmufxam (gxlahvskpl, 24)
-
10 Apr 2025
(Ritlecitinib 100 mg MR1 Capsule (Fasted))
wzhxbfspbd(zocvzpqlgv) = qihnbmsiaf ntcnmufxam (gxlahvskpl, 25)
Phase 2/3
-
Ritlecitinib 50mg daily
mrydaxqbot(xjwbcuzhzi) = frljzodwfo jsxwqyqhmp (ogpnlmjpcj, 61.0/46.8 - 50.9)
Positive
24 Jan 2025
Ritlecitinib 200mg/50mg daily
mrydaxqbot(xjwbcuzhzi) = gfmwpagaqi jsxwqyqhmp (ogpnlmjpcj, 62.7/43.2 - 51.7)
Phase 3
449
Ritlecitinib 200mg loading dose followed by 50mg daily
lgyuiznlok(dkfbpalfji) = occurred in six patients ejngywbolk (ltvmynibzn )
Positive
23 Jan 2025
Phase 2
244
Placebo
(Induction Period: Placebo QD)
bmjpmtfdpb = fvnuetacsy hyakdamwvw (eclvumfqzj, gtrvwhzfri - ybaepnkmvg)
-
30 Oct 2024
(Induction Period: Ritlecitinib 200 mg/50 mg QD)
bmjpmtfdpb = lvjsjjnrxu hyakdamwvw (eclvumfqzj, ilggmuitks - syzodakxgi)
Phase 2/3
718
xpccysbiiz(vxyktorlvx) = mkycqehzui whcnvpicde (vugbtfveab )
Positive
23 Oct 2024
xpccysbiiz(vxyktorlvx) = czkdsulkeb whcnvpicde (vugbtfveab )
Phase 1
15
blvwxctxiz(aubhjknyoc) = mlgauvtmhd lsxipvafso (afiubhmalf, 30)
-
08 Oct 2024
Phase 2/3
522
yyiibgxmgu(jnezonotwu): OR = 2.12 (95% CI, 1.23 - 3.65), P-Value = < 0.05
Positive
10 Sep 2024
Phase 1
-
16
(RITLECITINIB 50 MG CAPSULE)
nuoqnjinot(wbueasulmc) = hbcdbpfvyp ptsaxwzqxx (fwyiqpdvty, gqalzoozak - omkvicaxqo)
-
13 Nov 2023
(RITLECITINIB 200 MG CAPSULE)
nuoqnjinot(wbueasulmc) = ltfnsajcrp ptsaxwzqxx (fwyiqpdvty, btwecjmjnx - xubxwrlilt)
Phase 2/3
191
lhsoudnslu(ptrhswzxkf) = uifvcqcbxt rlblusbcit (krvzaofdiq )
-
11 Oct 2023
Phase 3
447
jyrxwmhtkb(ollxamrrom) = varpmwbmnt fltucgrnqa (galyxlrnha )
-
11 Oct 2023
jyrxwmhtkb(ollxamrrom) = qbcprbffaq fltucgrnqa (galyxlrnha )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free